ESC 2023 Update: Colchicine does not reduce primary outcomes in patients undergoing major non-cardiac thoracic surgery: COP-AF trial
Canada: In patients undergoing major non-cardiac thoracic surgery, colchicine fails to significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS), COP-AF trial has shown.
The findings were presented in a Hot Line session on August 26 at ESC (European Society of Cardiology) Congress 2023.
Perioperative AF occurs in approximately 10% of patients after major thoracic surgery, while MINS has an incidence of about 20% in the same patient population. Patients with perioperative AF and MINS have a poor prognosis. High levels of inflammatory biomarkers have been associated with an increased risk of perioperative AF and MINS. Anti-inflaEuropean Society of Cardiologymmatory treatment therefore has the potential to reduce the incidence of these two prognostically important complications. Colchicine is an inexpensive drug with anti-inflammatory effects. Small randomised trials have suggested that in patients undergoing cardiac surgery, low-dose colchicine reduces the risk of perioperative AF. Two large randomised trials found that low-dose colchicine significantly reduced the incidence of major cardiovascular outcomes in patients with coronary artery disease.
The COP-AF trial tested the hypothesis that colchicine reduces the incidence of clinically important perioperative AF and MINS in patients undergoing major non-cardiac thoracic surgery. The trial enrolled patients aged 55 years or older who were undergoing major non-cardiac thoracic surgery. Participants were randomly assigned in a 1:1 ratio to receive oral colchicine 0.5mg twice daily or a matching placebo, starting within four hours before surgery and for a total duration of 10 days. Two co-primary outcomes were assessed during 14 days of follow-up: 1) clinically important perioperative AF (i.e., AF needing medical treatment or AF leading to heart failure, hypotension or angina) and 2) MINS (i.e., myocardial infarction or any postoperative troponin elevation deemed to be of ischaemic origin).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.